作者: Harshad Shete , Sushmita Chatterjee , Abhijit De , Vandana Patravale
DOI: 10.1016/J.IJPHARM.2013.03.036
关键词:
摘要: Long chain lipid (LCL) based tamoxifen loaded nanostructured carriers (Tmx-NLCs) meant to target intestinal lymphatic systems (ILSs) was developed and characterized previously. The aim of the present work evaluate in vitro efficacy Tmx-NLC against breast cancer cell lines confirm hypothesis targeting ILS after single dose oral administration. In anticancer activity assessed human estrogen receptor expressing viz. MCF-7 ZR-75-1. study revealed relatively improved for compared free Tmx cells. However, compromised ZR-75-1 cells which could be attributed its up regulation MUC1 gene. Confocal flow cytometric analysis remarkable intracellular uptake localization nuclear perinuclear region exhibited distinctly different pharmacokinetic profile Tamoxifen suspension (Tmx-susp) an increment bioavailability by 2.71-fold prolonged T1/2 7.10-fold. Moreover, detectable drug concentration mesenteric lymph nodes justifies our explains major occur via system.